Inflammatory eye diseases research proves the effectiveness of biologic compounds. Currently frequent skin (SC) or vein (IV) injections are required for treatment. Much higher doses are necessary in order to be efficacious. Costs are substantial frequently in excess of $60,000/year.

An eye implant, slowly releasing the exact amount of compound needed, would significantly reduce the cost and complexity of treating uveitis, age related macular degeneration, and diabetic macular edema while reducing the complications associated with systemic biologics.

In addition, as company research into ocular inflammation continued we realized that a topical version of our product could reduce complications and improve the outcomes of refractive surgery (LASIK, LASEK, PRK, and epi-LASIK) and decrease scarring in corneal injury or infection.